Financial Survey: GSK (NYSE:GSK) and Organon & Co. (NYSE:OGN)

Organon & Co. (NYSE:OGN) and GSK (NYSE:GSK) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, earnings and valuation.

Insider & Institutional Ownership

77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by insiders. Comparatively, 10.0% of GSK shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Organon & Co. and GSK’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Organon & Co.	N/A	N/A	N/A
GSK	N/A	N/A	N/A

Valuation and Earnings

This table compares Organon & Co. and GSK”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.13 billion	0.59	$202.21 million	$0.77	17.85
GSK	N/A	N/A	N/A	$3.20	15.92

Organon & Co. has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings for Organon & Co. and GSK, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2	5	0	0	1.71
GSK	3	12	4	0	2.05

Organon & Co. presently has a consensus target price of $11.40, suggesting a potential downside of 17.06%. GSK has a consensus target price of $55.33, suggesting a potential upside of 8.59%. Given GSK’s stronger consensus rating and higher possible upside, analysts clearly believe GSK is more favorable than Organon & Co..

Summary

GSK beats Organon & Co. on 5 of the 7 factors compared between the two stocks.

About Organon & Co.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.